Biological Role of Estrogen Receptor β in Salivary Gland Adenocarcinoma Cells
Purpose: This study is intended to investigate the biological role of estrogen receptor (ER) nongenomic signaling in salivary gland adenocarcinoma cells that predominantly express ERβ. Experimental Design: Salivary gland adenocarcinoma cell lines HSG and HSY were used to study the effect of diarylpr...
Gespeichert in:
Veröffentlicht in: | Clinical cancer research 2006-10, Vol.12 (20), p.5994-5999 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Purpose: This study is intended to investigate the biological role of estrogen receptor (ER) nongenomic signaling in salivary gland
adenocarcinoma cells that predominantly express ERβ.
Experimental Design: Salivary gland adenocarcinoma cell lines HSG and HSY were used to study the effect of diarylpropionitrile and estrogen on
the nongenomic signaling of ERβ, cytoskeletal remodeling, and cell motility.
Results: We found that diarylpropionitrile and estrogen triggered rapid activation of the extracellular signal-regulated kinase 1/2
(ERK), Src, and focal adhesion kinase signaling pathways. Estrogen stimulation also induced long cytoplasmic extensions, filopodia
formation, and abnormal outgrowths in both HSG and HSY cells. We further observed that ligand-induced migration of these cells
was blocked by the pure antiestrogen ICI 182780 and the mitogen-activated protein/ERK kinase inhibitor PD98059, indicating
that estrogen-induced cell migration is mediated by the activation of ERβ nongenomic signaling.
Conclusion: These results clearly showed that ERβ nongenomic signaling is active in salivary gland cells and has a biological role in
migration, presumably via the stimulation of ERK1/2. In future, the findings of this study might have clinical importance
as several ERβ-selective agonists are currently being available, and these could potentially be used for therapeutic targeting
of ERβ-positive salivary tumors. |
---|---|
ISSN: | 1078-0432 1557-3265 |
DOI: | 10.1158/1078-0432.CCR-06-1251 |